Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Heidi C. Waters, Maelys Touya, Soon Nan Wee, Michelle Ng, Simran Thadani, Subina Surendran, Miguel Rentería, A. John Rush, Rashmi Patel, Joydeep Sarkar, Heather M. Fitzgerald & Xue Han. (2023) Psychiatric healthcare resource utilization following initiation of aripiprazole once-monthly: a retrospective real-world study. Current Medical Research and Opinion 39:2, pages 299-306.
Read now
Read now
Georgios Schoretsanitis, Ekkehard Haen, Daria Piacentino, Andreas Conca, Katharina Endres, Christoph Hiemke, Gerhard Gründer & Michael Paulzen. (2022) Effects of body weight, smoking status, and sex on plasma concentrations of once-monthly paliperidone palmitate. Expert Review of Clinical Pharmacology 15:2, pages 243-249.
Read now
Read now
Renato de Filippis, Pasquale De Fazio, Raffaele Gaetano, Luca Steardo, Clemente Cedro, Antonio Bruno, Rocco Antonio Zoccali & Maria Rosaria Anna Muscatello. (2021) Current and emerging long-acting antipsychotics for the treatment of schizophrenia. Expert Opinion on Drug Safety 20:7, pages 771-790.
Read now
Read now
Miquel Bioque & Miquel Bernardo. (2018) The current data on the 3-month paliperidone palmitate formulation for the treatment of schizophrenia. Expert Opinion on Pharmacotherapy 19:14, pages 1623-1629.
Read now
Read now
Tingjian Yan, Mallik Greene, Eunice Chang, Ann Hartry, Maëlys Touya & Michael S. Broder. (2018) All-cause hospitalization and associated costs in patients with schizophrenia or bipolar disorder initiating long-acting injectable antipsychotics. Current Medical Research and Opinion 34:1, pages 41-47.
Read now
Read now
Cristiana Montemagni, Tiziana Frieri & Paola Rocca. (2016) Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life. Neuropsychiatric Disease and Treatment 12, pages 917-929.
Read now
Read now
Miquel Bernardo & Miquel Bioque. (2016) Three-month paliperidone palmitate - a new treatment option for schizophrenia. Expert Review of Clinical Pharmacology 9:7, pages 899-904.
Read now
Read now
Articles from other publishers (23)
Gordon Shymko, Louise Dobson, Maria Cynthia Acacio, Terina Grace, Sarah Tadier & Flavie Waters. (2023) Weight changes in people with early psychosis treated with oral or long-acting injectable aripiprazole. Schizophrenia Research 251, pages 74-81.
Crossref
Crossref
Cecilio Álamo. (2022) Risperidone ISM as a New Option in the Clinical Management of Schizophrenia: A Narrative Review. Advances in Therapy 39:11, pages 4875-4891.
Crossref
Crossref
José Manuel Olivares & Andrea Fagiolini. (2022) Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis. Frontiers in Psychiatry 13.
Crossref
Crossref
L.A. Burygina, S.A. Golubev, A.Yu. Berezantsev & E.A. Shumakova. (2022) Transfer from paliperidone of one-month action to paliperidone of three-month action in schizophrenia spectrum disorders: clinical aspects, pharmacological strategies, therapeutic prediction. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 122:1, pages 13.
Crossref
Crossref
Vanteemar S. Sreeraj, Venkataram Shivakumar, Naren P. Rao & Ganesan Venkatasubramanian. 2022. Long-Acting Drug Delivery Systems. Long-Acting Drug Delivery Systems
203
222
.
Miquel Bernardo, Fernando Rico-Villademoros, Clemente García-Rizo, Rosa Rojo & Ricardo Gómez-Huelgas. (2021) Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies. Advances in Therapy 38:5, pages 2491-2512.
Crossref
Crossref
Rohan Mahabaleshwarkar, Dee Lin, Jesse Fishman, Todd Blair, Timothy Hetherington, Pooja Palmer, Charmi Patel, Carmela Benson, Kruti Joshi, Constance Krull & Oleg V. Tcheremissine. (2021) The Impact of Once-Monthly Paliperidone Palmitate on Healthcare Utilization Among Patients With Schizophrenia Treated in an Integrated Healthcare System: A Retrospective Mirror-Image Study. Advances in Therapy 38:4, pages 1958-1974.
Crossref
Crossref
Keisuke Asano, Takefumi Suzuki, Masaru Mimura & Hiroyuki Uchida. (2021) Prescription patterns in patients with schizophrenia who discontinued long‐acting injectable antipsychotics: A chart‐review. Psychiatry and Clinical Neurosciences.
Crossref
Crossref
Yusuke Iwata, Yu Aruga, Masataka Ohtsuki, Masahiro Inoue, Kazuyuki Yasuda, Takashi Hirata, Takuji Uemura & Takefumi Suzuki. (2021) Successful Introduction of Paliperidone Palmitate for Pregnant Woman With Schizophrenia. Journal of Clinical Psychopharmacology 41:2, pages 210-212.
Crossref
Crossref
Hitoshi Sakurai, Norio Yasui-Furukori, Takefumi Suzuki, Hiroyuki Uchida, Hajime Baba, Koichiro Watanabe, Ken Inada, Yuka Sugawara Kikuchi, Toshiaki Kikuchi, Asuka Katsuki, Ikuko Kishida & Masaki Kato. (2021) Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus. Pharmacopsychiatry 54:02, pages 60-67.
Crossref
Crossref
J. Leijala, O. Kampman, J. Suvisaari & S. Eskelinen. (2021) Daily functioning and symptom factors contributing to attitudes toward antipsychotic treatment and treatment adherence in outpatients with schizophrenia spectrum disorders. BMC Psychiatry 21:1.
Crossref
Crossref
José Manuel Olivares, Ana González-Pinto & Mario Páramo. (2021) Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study. European Psychiatry 64:1.
Crossref
Crossref
Nakao Iwata, Ataru Inagaki, Hiromi Sano, Kazunari Niidome, Yoshitsugu Kojima & Sakiko Yamada. (2020) Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan. Advances in Therapy 37:7, pages 3324-3336.
Crossref
Crossref
Sally Mustafa, Joanna Bougie, Maia Miguelez, Guerline Clerzius, Emmanouil Rampakakis, Jean Proulx & Ashok Malla. (2019) Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study. BMC Psychiatry 19:1.
Crossref
Crossref
Tingjian Yan, Mallik Greene, Eunice Chang, Michael S Broder, Maëlys Touya, Jennifer Munday & Ann Hartry. (2019) Hospitalization risk factors in antipsychotic-treated schizophrenia, bipolar I disorder or major depressive disorder. Journal of Comparative Effectiveness Research 8:4, pages 217-227.
Crossref
Crossref
KyuYoung Lee. (2019) The Long-Acting Injectable Antipsychotics in Clinical Practice. Journal of Korean Neuropsychiatric Association 58:1, pages 29.
Crossref
Crossref
Marit Tveito, Robert L. Smith, Espen Molden, Tore Haslemo, Helge Refsum, Cecilie Hartberg, Christoph U. Correll & Gudrun Høiseth. (2018) Age Impacts Olanzapine Exposure Differently During Use of Oral Versus Long-Acting Injectable Formulations. Journal of Clinical Psychopharmacology 38:6, pages 570-576.
Crossref
Crossref
Tingjian Yan, Mallik Greene, Eunice Chang, Ann Hartry, Maëlys Touya & Michael S. Broder. (2018) Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data. Advances in Therapy 35:10, pages 1612-1625.
Crossref
Crossref
Baoming He, Liang Yu, Suping Li, Fei Xu, Lili Yang, Shuai Ma & Yi Guo. (2018) Neuroprotective effect of lurasidone via antagonist activities on histamine in a rat model of cranial nerve involvement. Molecular Medicine Reports.
Crossref
Crossref
Fuminari MisawaTakefumi SuzukiYasuo Fujii. (2017) Effect of Clozapine vs Other Second-Generation Antipsychotics on Hospitalization and Seclusion. Journal of Clinical Psychopharmacology 37:6, pages 664-668.
Crossref
Crossref
Vanteemar S. Sreeraj, Venkataram Shivakumar, Naren P. Rao & Ganesan Venkatasubramanian. (2017) A critical appraisal of long acting injectable antipsychotics: Translating research to clinics. Asian Journal of Psychiatry 28, pages 57-64.
Crossref
Crossref
Giovanni Ostuzzi, Irene Bighelli, Ryuhei So, Toshi A. Furukawa & Corrado Barbui. (2017) Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies. Schizophrenia Research 183, pages 10-21.
Crossref
Crossref
Enrico Biagi, Enrico Capuzzi, Fabrizia Colmegna, Alessandra Mascarini, Giulia Brambilla, Alessandra Ornaghi, Jacopo Santambrogio & Massimo Clerici. (2017) Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly. Advances in Therapy 34:5, pages 1036-1048.
Crossref
Crossref